ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-OR21

Empagliflozin Blunts Renal Mg2+ Wasting and Restores Distal Tubule Sodium Chloride Cotransporter (NCC) and TRPM6 Expression in Rats with Cisplatin-Induced Hypomagnesemia

Session Information

Category: Fluid, Electrolytes, and Acid-Base Disorders

  • 1101 Fluid, Electrolyte, and Acid-Base Disorders: Basic


  • McCormick, James A., Oregon Health & Science University School of Medicine, Portland, Oregon, United States
  • Jesus, Erika Fernandes, Universidade de Sao Paulo, Sao Paulo, Brazil
  • Caetano, Marcos Vinícius, Universidade de Sao Paulo, Sao Paulo, Brazil
  • Luchi, Weverton M., Universidade Federal do Espirito Santo, Vitoria, ES, Brazil
  • Girardi, Adriana C. C., Universidade de Sao Paulo, Sao Paulo, Brazil

The chemotherapeutic agent cisplatin is known to cause hypomagnesemia and renal Mg2+ wasting. Damage to the distal convoluted tubule (DCT), a key site of regulated Mg2+ reabsorption, may contribute. Recent clinical studies suggest that SGLT2 inhibitors increase serum Mg2+ concentration in patients with diabetes. However, the potential therapeutic use of SGLT2 inhibitors in a scenario of cisplatin-induced hypomagnesemia has not been investigated. This study tested the hypothesis that the SGLT2 inhibitor empagliflozin (EMPA) attenuates cisplatin-induced hypomagnesemia in rats through effects on the DCT.


Male Wistar rats (10 weeks of age) were treated weekly with cisplatin (2.5 mg/kg/or vehicle, i.p.) for five weeks. After three weeks of treatment, cisplatin (Cis) and vehicle-treated (Ctrl) rats were randomized and orally treated or not with EMPA (10 mg/kg/day) for two weeks.


Cis-treated rats developed significant hypomagnesemia (1.42 ± 0.05 vs. 2.19 ± 0.03 mg/dl in Ctrl and 2.23 ± 0.03 mg/dl in Ctrl + EMPA, P < 0.0001) and increased fractional excretion (FE) of Mg2+ compared to control groups (14.3 ± 1.3 vs. 0.48 ± 0.10% in Ctrl and 0.65 ± 0.10% in Ctrl + EMPA, P < 0.0001). EMPA reduced FE Mg (2.2 ± 0.2 vs. 14.3 ± 1.3% vs. P < 0.0001) and restored Mg2+ serum levels in Cis-treated rats (2.21 ± 0.05 mg/dl). The mRNA and protein abundance of NCC and TRPM6 and NCC phosphorylation were reduced in Cis-treated rats and rescued by EMPA. EMPA-treated Ctrl rats displayed higher NCC and TRPM6 mRNA and protein expression and NCC phosphorylation levels than untreated Ctrl. The effects of cisplatin and EMPA on NCC were confirmed using a hydrochlorothiazide (HCTZ) challenge. The natriuretic response to HCTZ in Cis-treated rats was lower and in Ctrl + EMPA higher than the other groups of rats. No difference was found in the natriuretic response to HCTZ between controls and EMPA-treated Cis-rats. Remarkably, immunohistochemistry suggested that EMPA reversed Cis-induced DCT injury.


Empagliflozin blunts renal Mg2+ wasting and restores serum Mg2+ concentration in cisplatin-treated rats. The effects of the SGLT2 inhibitor were associated with reversal of DCT injury, rescue of expression of TRPM6, NCC, and phosphorylated NCC, and normalization of NCC activity.


  • NIDDK Support